在患有发作的儿童中优化维加巴特林剂量:一种人口药理动力学方法
Agathe Molimard1, Frantz Foissac2,3, Naïm Bouazza2,3
1Service de Neuropédiatrie et Maladies Métaboliques, Hôpital Necker-Enfants-malades, AP-HP, Université Paris Cité, Paris, France.
British journal of clinical pharmacology
|April 26, 2024
概括
这项研究开发了儿童维加巴特林的药理动力学模型,确定了有效的暴露范围,以预防眼部毒性和优化发作治疗.
科学领域:
- 药理动力学和药理动力学
- 儿科神经学 儿科神经学
- 药品安全 药品安全
背景情况:
- 维加巴特林是一种治疗儿童严重的抗药.
- 眼部毒性是一个显著的不良影响,剂量依赖.
- 了解vigabatrin暴露对于安全有效的治疗至关重要.
研究的目的:
- 开发儿童维加巴的种群药动力学模型.
- 确定可接受的治疗性暴露范围.
- 在性中,将暴露与治疗反应关联起来.
主要方法:
- 对79名患有的儿童进行了回顾性研究.
- 使用非线性混合效应建模 (Monolix2021) 进行人口药理动力学分析.
- 对发作的响应者和不响应者的分类.
主要成果:
- 一个两部分的模型确定了体重和肌素清除量作为关键因素.
- 对于响应者 (36%),95%的AUC0-24在264-549 mg.h.L-1.0之间.
- 在儿科患者中确定了vigabatrin可接受的暴露范围.
结论:
- 种群的药理动力学揭示了个体间的变异性驱动因素.
- 确定了儿童的可接受vigabatrin暴露范围.
- 目标度策略可以最大限度地减少过度暴露,并优化治疗.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
287
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
287
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
131
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
131
Antiepileptic Drugs: GABAergic Pathway Potentiators
388
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
388
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176
Analysis of Population Pharmacokinetic Data
252
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
252


